It's not inconsistency throughout the tablet, but the bioavailability over the interval between doses, but also residual effects. For example, after being on 100-200mg of Amiodarone for several weeks, you will have the iodine in your system for a number of weeks afterwards. So, Amiodarone has a high 'half-life' bioavailability. It's the same, although in the world of nuclear physics, with radioactive decay. Some medical shadow agents used in imaging have half-lives measured in a couple of hours, while cesium 137 has a half-life around 30 years. It means at the 30-year mark, approximately half of the radioactive decay will still be taking place.
I believe apixaban has a half-life near 12 hours, maybe more...I haven't checked and keep forgetting. So, a missed dose is not going to cause undue harm as some of it is always available to those who ingest it regularly otherwise. Even so, the process of creating tablets of drugs is high engineering stuff, and the 'mix' is quite homogenous. This has to be for one reason, and it's not so that a tablet can be cut in half (but that is a benefit of what follows): the reason is that the dose must be consistent
from tablet-to-tablet. You can't expect that and not have homogeneity across a sample of randomly selected tablets, which is how you get them from the pharmacy and how you ingest them when you select one from the vial.